The Dama Newsletter: October Edition
Hello everyone,
Two big updates this month: ACOG just released a new guideline focused on menopause care, and we have a new generic patch on the market, aimed at improving access to menopause hormone therapy.
In this newsletter, we’ll talk about how the latest ACOG update compares to their 2014 edition and what the FDA's recent generic patch approval means for clinical practice.
TL;DR
✔️ The 2026 ACOG Guideline Paradigm Shift: For the first time since 2014, ACOG has released their updated menopause guidelines. The update formally shifts away from "lowest dose for the shortest duration" and an arbitrary stop at age 65. We are replacing it with shared decision-making. The new guideline also focuses on the "symptomatic triad" (vasomotor symptoms, sleep, mood), supports initiating MHT within the 10-year window of opportunity, and formalizes modern approaches like using the off-label 52-mg levonorgestrel IUD for endometrial protection.
✔️ Generic Patches & The Bioequivalence “Swing”: The FDA approved the first generic weekly estradiol/levonorgestrel patch given the ongoing national shortage. While therapeutically equivalent on paper, the FDA’s generic bioequivalence window (80% to 125%) can result in distinct total systemic estrogen exposure differences when patients switch between patches. Clinicians should consider these pharmacokinetic variations and differences in patch adhesives closely.
ACOG’s New and Expanded Guideline
ACOG updated its clinical practice guidelines for the first time since 2014, performing a comprehensive literature review and incorporating expert opinion on human-only studies published between 2013 and early 2024. The updated guidelines represent a paradigm shift from women surviving a “transition” to proactively managing this profound neuroendocrine transition. Importantly, it focuses on the "symptomatic triad" of vasomotor symptoms, sleep, and mood.
Let’s compare the two versions and assess how the clinical guidance has evolved (and how it caught up to things many of you are already very familiar with and have been doing for a while now!):
Redefining the Menopausal Transition and the “Symptom Triad”
In 2014, ACOG defined menopause broadly as “climacteric,” specifically a retrospective diagnosis based on 12-month cessation of menses with a median age of 51 years. However, the new guidelines use the STRAW +10 criteria, defining the exact boundaries of the early transition (cycle variability) and late transition (≥ 60 days of amenorrhea), while distinguishing spontaneous menopause (mean age of 49.9 years) from induced menopause and early menopause (ages 40-45).
Moreover, the guidelines reframed the clinical presentation of menopause around a bidirectional “symptomatic triad” of vasomotor symptoms, sleep disturbance, and mood changes. The 2026 guideline synthesizes longitudinal data from the Study of Women’s Health Across the Nation (SWAN), which demonstrated strong bidirectional links between VMS and sleep disruption, as well as VMS and frequent mood changes (such as irritability and tearfulness). The data also demonstrated that high baseline levels of depression or anxiety strongly predicted the co-occurrence of all three symptoms, although individual-specific, fluctuating symptom patterns remained common.
Figure 1. The “symptomatic triad” of vasomotor symptoms, sleep disturbance, and mood changes.
This shift is driven by contemporary understandings of neuroendocrine manifestations. During the menopause transition, declining estrogen removes the negative feedback on the hypothalamic kisspeptin/neurokinin B/dynorphin (KNDy) neurons. These neurons become hyperactive and secrete neurokinin B, overstimulating the thermoregulatory center in the hypothalamus and increasing vasomotor symptoms. This disruption not only affects thermoregulation but also directly drives sleep disturbances. Consequently, these sleep disturbances in turn exacerbate HPA-axis dysregulation and mood instability (1). While these mechanisms are exacerbated during perimenopausal depression and anxiety as a result of neurotransmitter changes, HPA-axis dysregulation, and neuroinflammatory pathways, the guidelines note that prior history of Major Depressive Disorder (MDD) is the strongest risk factor.
For symptoms of depression, the 2026 guideline clarifies that the evidence is insufficient to recommend for or against MHT. They state that MHT may offer benefits during perimenopause; postmenopausal depression or Major Depressive Disorder (MDD) should be recognized and treated with antidepressants or cognitive behaviour therapy (CBT). This is in alignment with the FIGO global framework for differentiating hormonal mood disturbances from depression, which we discussed in our March newsletter here.
Finally, the guideline also addressed care gaps and disparities. The 2014 guidelines recognized racial differences in symptoms, presenting SWAN reporting data showing Black women reported more hot flushes and Asian women reported fewer, but speculated this was due to dietary or cultural factors. In the updated guidelines, ACOG explicitly addresses systemic barriers as a primary cause, citing evidence that demonstrates Black women experience greater symptom severity and duration, yet are significantly less likely to receive treatment due to systemic racism and unequal access to care (2). Importantly, it also addresses barriers facing transgender, gender-diverse, and sexual minority individuals, including clinician bias, a lack of culturally competent care, and the absence of standardized definitions for non-cisgender menopause (3).
Modern take on MHT formulations
Historically, studies and clinical discourse often lumped all MHT together, broadly recommending different routes of administration as largely interchangeable. However, the updated 2026 guidelines consider formulation far more precisely. Drawing on meta-analyses, ACOG recognizes transdermal 17β-estradiol combined with a progestogen as a safe modality for reducing both vasomotor frequency and sleep disturbances in women with an intact uterus. While the 2014 bulletin had no formal recommendation for sleep, the 2026 guideline introduced a strong recommendation for systemic MHT to manage vasomotor-related sleep disturbance.
The nuance here is that while transdermal 17β-estradiol is favorable due to its ability to bypass the liver and minimize the thrombotic risks, the clinical reality is that there are specific patient phenotypes where alternative routes or estrogen types are actually clinically superior.
Furthermore, transdermal absorption is highly variable. Patients may not achieve therapeutic serum estradiol levels due to individual differences in skin thickness, lipid content, or severe contact dermatitis from patch adhesives (4). These limitations may necessitate alternative administrative routes, such as oral formulations or systemic vaginal rings (e.g., Femring).
Interestingly, ACOG appears to be one of the first large governing bodies to support the forward-leaning practice of using the off-label 52-mg levonorgestrel-releasing IUD to provide endometrial protection alongside systemic estrogen for up to five years. Additionally, for patients wanting to avoid progestogen-related side effects such as breast tenderness or irregular bleeding, ACOG provides a formal conditional recommendation for Tissue Selective Estrogen Complexes (TSECs; pairing conjugated estrogens with bazedoxifene) to protect the endometrium without stimulating breast tissue (6).
The nuance, however, is that when discussing progestogens, not all progestogens carry the same risk profile. Large observational studies, such as the French E3N cohort, have consistently demonstrated that older, synthetic progestins (such as MPA) are associated with a higher relative risk of breast cancer compared to newer, body-identical forms of progesterone, such as micronized progesterone (5). In future iterations of the guidelines, moving away from a class-wide grouping of “progestogens” and officially stratifying them by their long-term breast cancer and cardiometabolic risk profiles will be increasingly valuable for clinical decision support.
Lastly, the guideline establishes a clear evaluation criteria for vaginal bleeding, that is: while unscheduled or breakthrough bleeding is common and expected during the first 3 months as endometrial tissue adjusts, any bleeding persisting after 6 months is considered abnormal and requires a formal diagnostic workup to explicitly rule out endometrial intraepithelial neoplasia and cancer.
Reframing Risk and Revising the “Shortest Duration” Recommendation
One of the biggest paradigm shifts between the two guidelines is how ACOG presents advice on risk stratification and treatment duration. The 2014 guidelines relied heavily on cumulative WHI data to justify the strict “lowest effective dose for the shortest duration” mandate. The 2026 guidelines radically recontextualize the WHI, explicitly reminding clinicians that 67% of the trial’s participants were over the age of 60 at enrollment. When separating older women who started hormone therapy late from younger populations, the data shows that healthy candidates aged 50 to 59, or within 10 years of menopause onset, have extremely low absolute risks.
ACOG specifically points to the Cochrane meta-analysis of 19 trials that demonstrated a 48% reduction in coronary heart disease and a stroke risk similar to placebo when therapy was initiated in this window (7), while secondary WHI re-analyses confirmed no statistically significant increase in atherosclerotic cardiovascular disease among newly menopausal individuals with vasomotor symptoms (8). Aligning with the FDA’s 2025 decision to remove the boxed warnings on cardiovascular disease, breast cancer, and probable dementia from estrogen-containing drugs, ACOG now suggests using validated, objective screening tools, such as the ACC/AHA ASCVD Risk Estimator Plus, the NCI Breast Cancer Risk Assessment Tool, or the Tyrer-Cuzick model, to guide initiation during the “optimal window” with safety.
Importantly, when detailing guidelines for absolute contraindications, ACOG introduced a nuanced exception that expanded recommendations for MHT use in women with cancer. The guidelines explicitly stated that MHT may be considered in women with early-stage endometrial cancer or high-grade serous ovarian cancer, provided that there is shared decision-making and direct consultation with a gynecologic oncologist.
Instead of the “shortest duration” mandate, the guidelines affirm that continuing MHT past age 60 is clinically appropriate to curb quality-of-life-limiting symptoms, provided the benefit-risk profile for the individual remains favorable.
Clinical Pearls
✔️ Long-term MHT use: The 2026 guidelines have confirmed that MHT can be continued indefinitely if the quality-of-life benefits outweigh individualized risks.
✔️ Screen for the "Symptomatic Triad," Not Just Hot Flashes: Screen for sleep disturbance and mood changes beyond hot flushes. Always distinguish between hormonal mood changes and MDD. While MHT can support mood by resolving sleep disturbance, clinical MDD should be treated with first-line SSRIs/SNRIs and CBT.
✔️ Leverage Modern Formulations: ACOG now explicitly supports prescribing MHT by formulation and route of administration, including transdermal 17β-estradiol, Tissue Selective Estrogen Complexes (TSECs) for those avoiding progestogens, and the off-label use of the 52-mg levonorgestrel IUD for up to 5 years of endometrial protection.
FDA Approves First Generic Estradiol/Levonorgestrel Weekly Patch
For months, the narrative on social media and news outlets has highlighted a shared frustration: the estrogen patch shortage. From 2024 to May 2026, U.S. prescriptions surged from 594,000 to over 1.6 million. This spike likely followed the landmark FDA label revisions that finally removed black box warnings on MHT. As a result, pharmacies are struggling to keep patches in stock.
Interestingly, there is a regulatory disconnect regarding this supply chain issue. The American Society of Health-System Pharmacists (ASHP) has declared an ongoing shortage across multiple estrogen patch brands based on localized, pharmacy-level stockouts. However, the FDA has not declared an official national shortage, noting that overall manufacturing output has actually doubled due to the rise in demand following the black box warning removal. Because the FDA has not announced an official patch shortage, manufacturers are not formally pressured to expedite production or import from foreign suppliers, and insurance companies are not pressured to cover alternative brands. Consequently, patients are left paying out of pocket, abruptly stopping therapy, or skipping doses, leading to symptom relapse.
In an effort to increase market competition and accessibility, the FDA recently approved the first generic of Climara Pro by Zydus Pharmaceuticals. This once-a-week transdermal system delivers 0.045 mg of estradiol and 0.015 mg of levonorgestrel daily. It is indicated specifically for women with an intact uterus, as the levonorgestrel component offsets the endometrial hyperplasia risk of unopposed estrogen.
While the FDA press release classifies this generic as therapeutically equivalent to the brand-name reference drug, Climara Pro, there are important clinical nuances to consider when patients switch between generic and brand MHT.
To receive FDA approval, generic manufacturers submit an Abbreviated New Drug Application (ANDA). They are not required to conduct Phase III clinical trials to prove symptom reduction; instead, they must prove pharmacokinetic bioequivalence. By FDA standards, a generic is considered bioequivalent if the 90% confidence interval of the generic-to-brand ratio for both peak serum concentration (Cmax) and total exposure (AUC) falls within 80% to 125%. While this statistical window is perfectly acceptable at a population level, it can result in highly variable responses for the individual patient.
Let’s use a hypothetical example: Imagine a highly sensitive patient who is stable on a brand-name patch, like Climara Pro. According to the Climara Pro’s FDA label, at Week 4, Climara Pro delivers a total estradiol exposure of approximately 6,002 pg·h/mL. Due to insurance formulary changes, she is switched to a comparable “Generic A,” which actually operates at the lower end of the FDA bioequivalence window (85% of the brand's systemic exposure, or roughly 5,102 pg·h/mL). She tolerates this slight dip well, and her body adjusts to the new baseline. Months later, due to a pharmacy supply chain issue, she is dispensed a comparable “Generic B.” This patch operates at the higher end of the permissible window (120% of the brand's exposure, or roughly 7,202 pg·h/mL). On paper, the clinician sees the same prescribed "dose." In reality, the patient’s total systemic estrogen exposure just jumped by 2,100 pg·h/mL, a very significant swing in systemic estrogen exposure. Compared to the Generic A patch her body was used to, Generic B is delivering a massive 41% increase in estrogen exposure. Pharmacokinetic differences as we switch between brands and generics can be the underlying reasons behind sudden symptom relapses or new side effects.
Another complication to consider is that generic estradiol patches are not always structurally identical to brand-name matrix patches. Generic manufacturers often use different adhesives, penetration enhancers, and proprietary delivery technologies. These differences interact differently with a patient’s skin lipid content and sweat, which means they may not stick as well; clinically, poor adhesion means lower, less predictable estrogen absorption.
✔️ Clinical Takeaway: When a stable patient reports a sudden relapse of vasomotor symptoms, mood changes, or new side effects (like spotting or breast tenderness) after a MHT switch, check the manufacturer. Pharmacokinetic differences between generics can be the culprit.
Conclusion
The guidelines are moving in the right direction - the direction that probably supports what you’ve already been doing in practice. We are going to be watching for other updates, especially around cardiovascular health, osteoporosis management, brain fog management and testosterone prescribing.
As the demand for comprehensive, personalized hormone care continues to surge, the ability to tailor prescribing, understand pharmacokinetic nuances, and confidently navigate opportunities for prevention will be what separates standard care from optimal care.
Warmly,
The Dama Health team